Financial Performance - The company's operating revenue for 2024 was CNY 13,465,627,318.38, a decrease of 7.55% compared to CNY 14,566,039,611.98 in 2023[19] - The net profit attributable to shareholders for 2024 was CNY 2,583,058,408.54, down 43.01% from CNY 4,532,483,532.14 in 2023[19] - The net profit after deducting non-recurring gains and losses was CNY 2,830,448,069.60, a decrease of 37.32% compared to CNY 4,515,660,901.70 in 2023[19] - The basic earnings per share for 2024 was CNY 6.42, a decline of 42.73% from CNY 11.21 in 2023[19] - The total cash dividends distributed for the year amounted to CNY 1,047,473,211.20, accounting for 56.81% of the annual net profit[5] - The company achieved a revenue of 13.466 billion yuan, a decrease of 7.55% compared to the same period last year[48] - The net profit attributable to shareholders was 2.583 billion yuan, down 43.01% year-on-year[48] - R&D investment reached 2.690 billion yuan, an increase of 11.20%, accounting for 19.97% of total revenue[49] - Sales expenses increased by 11.81% to 4.439 billion yuan, reflecting enhanced sales team recruitment and compliance efforts[50] Assets and Cash Flow - The total assets at the end of 2024 were CNY 31,051,118,040.40, representing a 1.00% increase from CNY 30,743,650,924.81 at the end of 2023[19] - The net assets attributable to shareholders increased by 4.19% to CNY 22,999,514,866.29 at the end of 2024, compared to CNY 22,074,934,790.14 at the end of 2023[19] - The cash flow from operating activities for 2024 was CNY 3,104,279,406.34, down 39.18% from CNY 5,103,687,813.05 in 2023[19] - The net cash flow from operating activities decreased by 39.18% to ¥3,104,279,406.34 in 2024 from ¥5,103,687,813.05 in 2023[109] Market and Industry Trends - The healthcare industry is increasingly important due to population aging and rising health awareness, with significant growth opportunities in the biopharmaceutical sector[28] - In 2024, the government aims to enhance the medical insurance system and promote the development of innovative drugs and medical devices[29] - The company is positioned to benefit from ongoing reforms in centralized drug procurement and medical insurance adjustments, enhancing market access and competitiveness[33] Product Development and Innovation - The company focuses on biopharmaceuticals and traditional Chinese medicine, with business segments covering gene engineering, biological vaccines, antibody drugs, high-end pharmaceuticals, and modern traditional Chinese medicine[35] - The gene engineering pharmaceutical segment, through its subsidiary JinSai Pharmaceutical, emphasizes children's and women's health, while also expanding into adult endocrine, dermatology, and oncology[36] - Key products include growth hormone series, follicle-stimulating hormone, and nutritional products, targeting various growth disorders in children[37] - The company is actively involved in the development of children's medications, responding to national policies aimed at improving pediatric healthcare services[34] - The company has introduced innovative products such as AI-based bone age assessment tools and growth development measurement devices[37] Regulatory Compliance and Governance - The company is focused on compliance and regulatory standards, responding to increased scrutiny in the pharmaceutical industry[32] - The company received an "A" rating in the annual information disclosure assessment by the Shenzhen Stock Exchange for 2024[142] - The company achieved a "AAA" rating in the ESG index assessment by the Shenzhen Stock Exchange[142] - The company has implemented a "Quality and Return Dual Improvement" action plan to enhance shareholder value and corporate governance[140] Environmental Compliance - The company has received various environmental permits, ensuring compliance with pollution discharge standards[194] - The company reported a chemical oxygen demand (COD) discharge of 15.38 mg/L, with a total of 0.4915 tons per year[1] - The company achieved a non-methane total hydrocarbon emission of 1.11 mg/Nm³, meeting the emission standards[2] - The company is focused on maintaining low emissions and adhering to environmental standards across all facilities[196] Strategic Partnerships and Acquisitions - The company acquired 100% of Changchun Yunxi Biopharmaceutical Co., Ltd. in 2024, expanding its operational scope[99] - The company has established strategic partnerships with multiple universities and hospitals to enhance research and clinical application, promoting innovation in medical technology[86] Employee and Management Structure - The company has a total of 11,547 employees, with 4,995 in sales, 3,808 in production, and 1,703 in technical roles[173] - The company has implemented a performance-linked floating salary system to enhance employee motivation and ensure high-quality development[174] - The company has a total of seven senior management personnel, ensuring effective daily operations and management[145] Future Outlook - The company provided an optimistic outlook for the next quarter, projecting a revenue increase of 25% to $625 million[155] - New product launches are expected to contribute an additional $50 million in revenue over the next fiscal year[156] - The company plans to expand its market presence and enhance product development in the upcoming fiscal year[152]

Financial Performance - The company's revenue for Q1 2025 was CNY 2,997,478,589.10, a decrease of 5.66% compared to CNY 3,177,355,203.27 in the same period last year[5] - Net profit attributable to shareholders was CNY 472,704,862.34, down 44.95% from CNY 858,728,236.98 year-on-year[5] - The basic earnings per share decreased to CNY 1.17, a decline of 45.07% compared to CNY 2.13 in the previous year[5] - Total operating revenue decreased to CNY 2,997,478,589.10 from CNY 3,177,355,203.27, representing a decline of approximately 5.65% year-over-year[19] - Total operating costs increased to CNY 2,422,413,505.22 from CNY 2,102,994,280.55, marking an increase of about 15.19% year-over-year[19] - Net profit attributable to the parent company decreased to CNY 472,704,862.34 from CNY 858,728,236.98, a decline of approximately 44.93% year-over-year[20] - Basic earnings per share decreased to CNY 1.17 from CNY 2.13, reflecting a drop of about 45% year-over-year[21] - Total comprehensive income decreased to CNY 468,710,472.39 from CNY 889,346,936.00, a decline of approximately 47.3% year-over-year[21] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 571,068,215.38, representing a 49.72% decrease from CNY 1,135,769,256.97 in the same period last year[5] - The net cash flow from investing activities was -2,697,676,383.92, indicating a significant outflow compared to the previous period's outflow of -659,395,909.82[24] - The net cash flow from financing activities was -75,189,681.00, a decrease from -480,108,431.16 in the prior period, reflecting reduced cash outflows[24] - The total cash and cash equivalents at the end of the period amounted to 3,828,444,255.44, down from 7,535,306,650.71 at the beginning of the period[24] - The cash and cash equivalents net increase for the period was -2,202,162,630.64, compared to -3,747,375.91 in the previous period[24] - Cash paid for debt repayment was 207,984,031.57, significantly lower than 629,301,008.75 in the prior period[24] - The company distributed dividends and interest payments totaling 17,251,796.63, compared to 9,345,037.33 previously[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 31,696,330,314.92, an increase of 2.08% from CNY 31,051,118,040.40 at the end of the previous year[5] - Total current assets decreased from CNY 16,270,250,650.56 to CNY 15,973,804,458.05, a decline of approximately 1.8%[15] - Total liabilities increased from CNY 4,948,673,308.81 to CNY 5,133,838,859.72, an increase of about 3.7%[17] - Total non-current assets increased from CNY 14,780,867,389.84 to CNY 15,722,525,856.87, an increase of approximately 6.4%[16] - Total equity attributable to shareholders increased to CNY 23,472,599,231.87 from CNY 22,999,514,866.29, an increase of approximately 2.05%[18] - Total liabilities and equity increased to CNY 31,696,330,314.92 from CNY 31,051,118,040.40, reflecting an increase of about 2.08%[18] Research and Development - The company continues to accelerate the R&D of key new products, including Class 1 innovative drugs, leading to increased R&D expenditures[10] - Research and development expenses increased to CNY 513,603,621.78 from CNY 421,532,747.26, an increase of about 21.8% year-over-year[20] Other Financial Metrics - The company reported a significant increase in sales personnel, contributing to higher expenses and impacting net profit[10] - Other comprehensive income after tax decreased to CNY -706,693.40 from CNY -2,362,751.60, indicating an improvement in losses[21] - The impact of exchange rate changes on cash and cash equivalents was -364,781.10, a minor change from -12,291.90 in the previous period[24] - The first quarter report was not audited, indicating that the financial data may be subject to further review[25] - The company will implement new accounting standards starting in 2025, which may affect future financial reporting[26]

证券代码：000661 证券简称：长春高新 公告编号：2025-021 长春高新技术产业（集团）股份有限公司 关于回购股份进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）于2024年 11月14日召开了第十一届董事会第六次会议，审议通过了《关于公司回购股份 方案的议案》，同意公司使用自有资金及金融机构股票回购专项贷款资金以集 中竞价交易方式回购部分公司已在境内发行的人民币普通股（A股）股票，全 部用于后续实施公司及子公司核心团队股权激励或员工持股计划。拟用于回购 资金总额不低于人民币3亿元（含）、不超过人民币5亿元（含），回购价格不 超过人民币160.00元/股。具体回购股份数量以回购期限届满时实际回购的股份 数量为准。 上述内容详见公司于2024年11月16日、2024年11月21日在《中国证券报》 《证券时报 》 《 上 海 证 券 报 》 《 经 济 参 考 报 》 及 巨 潮 资 讯 网 （ http://www.cninfo.com.cn）上分别披露的《关于公司回购股份方案暨取得 ...

一、药品的基本情况 产品名称：GenSci128 片 申请事项：境内生产药品注册临床试验 受理号：CXHL2500079，CXHL2500080，CXHL2500081 申请人：长春金赛药业有限责任公司 审批结论：同意本品开展临床试验 适应症：携带TP53 Y220C突变的局部晚期或转移性实体瘤 证券代码：000661 证券简称：长春高新 公告编号：2025-022 长春高新技术产业（集团）股份有限公司 关于子公司 GenSci128 片临床试验申请 获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品监督 管理局核准签发的《药物临床试验批准通知书》，金赛药业 GenSci128 片的境内 生产药品注册临床试验申请获得批准，现将相关情况公告如下： 公司将积极推进上述研发项目，并严格按照有关规定及时对项目后续进展 情况履行信息披露义务。 特此公告 长春高新技术产业（集团）股份有限公司 二、药品的其它情况 TP53 是人 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）于2024年12月24日召开的第十一届董事会 第七次会议、第十一届监事会第六次会议及2025年1月22日召开的2025年第一次临时股东大会，审议通 过了《关于变更部分回购股份用途并注销的议案》《关于减少注册资本并修订〈公司章程〉的议案》， 同意将注册资本由人民币肆亿零柒佰玖拾捌万壹仟肆佰贰拾玖元变更为肆亿零柒佰玖拾叁万柒仟伍佰贰 拾玖元。具体内容详见公司在巨潮资讯网上披露的《第十一届董事会第七次会议决议公告》《第十一届 监事会第六次会议决议公告》《关于变更部分回购股份用途并注销的公告》《关于变更注册资本并修订 〈公司章程〉的公告》《2025年第一次临时股东大会决议公告》等相关公告。 近日，公司已在长春市市场监督管理局长春新区分局办理完成工商变更登记手续并换领了营业执照，公 司注册资本已变更为肆亿零柒佰玖拾叁万柒仟伍佰贰拾玖元。除该项变更事项外，公司营业执照记载的 其他事项未发生变化。 特此公告 长春高新技术产业（集团）股份有限公司 登录新浪财经APP 搜索【 ...

关于减少注册资本完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）于 2024 年 12 月 24 日召开的第十一届董事会第七次会议、第十一届监事会第六次会议及 2025 年 1 月 22 日召开的 2025 年第一次临时股东大会，审议通过了《关于变更部分回购股份用途 并注销的议案》《关于减少注册资本并修订<公司章程>的议案》，同意将注册资本由人 民币肆亿零柒佰玖拾捌万壹仟肆佰贰拾玖元变更为肆亿零柒佰玖拾叁万柒仟伍佰贰 拾玖元。具体内容详见公司在巨潮资讯网上披露的《第十一届董事会第七次会议决议 公告》《第十一届监事会第六次会议决议公告》《关于变更部分回购股份用途并注销的 公告》《关于变更注册资本并修订<公司章程>的公告》《2025 年第一次临时股东大会决 议公告》等相关公告。 证券代码：000661 证券简称：长春高新 公告编号：2025-020 长春高新技术产业（集团）股份有限公司 特此公告 长春高新技术产业（集团）股份有限公司 董事会 2025 年 3 月 28 日 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-019 长春高新技术产业（集团）股份有限公司 关于子公司 GenSci120 注射液新药临床试验申请 获得美国食品药品监督管理局默示许可的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股子 公司长春金赛药业有限责任公司（以下简称"金赛药业"）收到美国食品药品监 督管理局（以下简称"美国 FDA"）通知，金赛药业 GenSci120 注射液新药临床 试验申请获得默示许可。现将相关情况公告如下： 一、药品的基本情况 类风湿关节炎（RA）是一种以侵蚀性关节炎症为主要临床表现的自身免疫 病。RA 全球患病率约 0.27%，总患病人数约 2000 万；美国 RA 患病率根据最新 的健康保险数据统计在 0.54%～0.63%之间。我国患病率约为 0.42%，患者总数 约 500 万，男女比约为 1:4①。尽管已有较多靶向药物获批，但仍有相当一部分患 ①Finckh, A., Gilbert, B., Hodkinson, B.et al. ...

长春高新技术产业（集团）股份有限公司 关于子公司聚乙二醇重组人生长激素注射液 增加国内同品种已批准适应症补充申请 获得国家药监局批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）聚乙二醇重组人生 长激素注射液（商品名：金赛增）增加国内同品种已批准适应症补充申请获得国 家药品监督管理局批准。现将相关情况公告如下： 一、药品的基本情况 产品名称：聚乙二醇重组人生长激素注射液（商品名：金赛增） 申请事项：增加国内同品种已批准适应症补充申请 受理号：CYSB2400329，CYSB2400330 申请人：长春金赛药业有限责任公司 规格：54IU/9.0mg/1.0ml/瓶，27IU/4.5mg/0.5ml/瓶 审批结论：符合药品注册的有关要求，批准本品 54IU/9.0mg/1.0ml/瓶规格增 加国内同品种已批准的适应症：用于性腺发育不全（特纳综合征）所致女孩的生 长障碍；用于特发性身材矮小（ISS）。批准本品 27IU/4.5mg/0 ...

根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引 第9号——回购股份》等相关法律法规的规定，公司在回购期间应当在每个月的 前三个交易日内公告截至上月末的回购进展情况。现将截至2025年2月28日的回 购股份进展情况公告如下： 长春高新技术产业（集团）股份有限公司（以下简称"公司"）于2024年 11月14日召开了第十一届董事会第六次会议，审议通过了《关于公司回购股份 方案的议案》，同意公司使用自有资金及金融机构股票回购专项贷款资金以集 中竞价交易方式回购部分公司已在境内发行的人民币普通股（A股）股票，全 部用于后续实施公司及子公司核心团队股权激励或员工持股计划。拟用于回购 资金总额不低于人民币3亿元（含）、不超过人民币5亿元（含），回购价格不 超过人民币160.00元/股。具体回购股份数量以回购期限届满时实际回购的股份 数量为准。 上述内容详见公司于2024年11月16日、2024年11月21日在《中国证券报》 《证券时报 》 《 上 海 证 券 报 》 《 经 济 参 考 报 》 及 巨 潮 资 讯 网 （ http://www.cninfo.com.cn）上分别披露的《关于公司回购股份方案 ...

证券代码：000661 证券简称：长春高新 GenSci098 注射液：用于治疗甲状腺眼病的 GenSci098 注 射液（人源化抗 TSHR 拮抗型单克隆抗体）已于 2024 年 8 月 获得境内临床试验批准和美国 FDA 新药临床试验默示许可， 公司正积极推动该产品的临床试验相关工作。 GenSci122 片：用于晚期实体瘤的化学药品 1 类新药 GenSci122 片（具有新型结构的选择性小分子 KIF18A 抑制剂） 已于 2024 年 10 月获得美国 FDA 新药临床试验默示许可，于 2024 年 12 月获得境内临床试验批准，公司正积极推动该产品 的临床试验相关工作。 GS1-144 片：用于绝经期血管舒缩症适应症的化学药品 1 类新药 GS1-144 片（NK3R 小分子拮抗剂）已于 2023 年 11 月 获得境内临床试验批准，于 2024 年 12 月获得美国 FDA 新药 临床试验默示许可。 长春高新技术产业（集团）股份有限公司 投资者关系活动记录表 编号：2025-001 投资者关系活动 类别 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ...